CURRICULUM VITAE - Tabula Rasa HealthCare · 2019-03-27 · CURRICULUM VITAE VERONIQUE MICHAUD,...

of 28/28
CURRICULUM VITAE VERONIQUE MICHAUD, B.SC. PHARM., Ph.D. Tabula Rasa HealthCare (TRHC) TRHC Scientific Precision Pharmacotherapy Research & Development Institute (SPPRDI) Chief Operating Officer 13485 Veteran’s Way, Lake Nona, Orlando, FL, 32827 Phone number: (856) 938-8697 Email: [email protected] Actual Position 2019/01 – Chief operating officer TRHC Scientific Precision Pharmacotherapy Research & Development Institute Lake Nona, Orlando, FL 2017/08 – Adjunct professor, Indiana University School of medicine, Clinical Pharmacology Department Indianapolis, IN 2016/09 – Adjunct professor, Associate Researcher position CRCHUM Faculté de Pharmacie, Université de Montréal, Montreal, Que, Canada Previous Positions 2018/01 –2018/12 Associate professor College of Pharmacy, University of Florida Pharmacotherapy and Translational Research Department Lake Nona, Orlando, FL, USA 2016/10 – 2017/12 V.P. Scientific Affairs, TabulaRasa Health Care Moorestown, NJ, USA 2012/04 – 2016/09 Assistant professor, Full Researcher position CRCHUM Faculté de Pharmacie, Université de Montréal, Montreal, Que, Canada 2014 – 2017 Scientific Director Pharmacokinetic and Bioanalytic core facility CRCHUM Montreal, Que, Canada
  • date post

    26-Jul-2020
  • Category

    Documents

  • view

    9
  • download

    0

Embed Size (px)

Transcript of CURRICULUM VITAE - Tabula Rasa HealthCare · 2019-03-27 · CURRICULUM VITAE VERONIQUE MICHAUD,...

  • CURRICULUM VITAE VERONIQUE MICHAUD, B.SC. PHARM., Ph.D.

    Tabula Rasa HealthCare (TRHC)

    TRHC Scientific Precision Pharmacotherapy Research & Development Institute (SPPRDI)

    Chief Operating Officer

    13485 Veteran’s Way, Lake Nona, Orlando, FL, 32827

    Phone number: (856) 938-8697

    Email: [email protected]

    Actual Position

    2019/01 – Chief operating officer TRHC Scientific Precision Pharmacotherapy Research &

    Development Institute Lake Nona, Orlando, FL

    2017/08 – Adjunct professor, Indiana University School of medicine, Clinical Pharmacology Department Indianapolis, IN

    2016/09 – Adjunct professor, Associate Researcher position CRCHUM Faculté de Pharmacie, Université de Montréal, Montreal, Que, Canada

    Previous Positions

    2018/01 –2018/12 Associate professor

    College of Pharmacy, University of Florida

    Pharmacotherapy and Translational Research Department

    Lake Nona, Orlando, FL, USA

    2016/10 – 2017/12 V.P. Scientific Affairs, TabulaRasa Health Care Moorestown, NJ, USA 2012/04 – 2016/09 Assistant professor, Full Researcher position CRCHUM Faculté de Pharmacie, Université de Montréal, Montreal, Que, Canada

    2014 – 2017 Scientific Director Pharmacokinetic and Bioanalytic core facility CRCHUM Montreal, Que, Canada

    mailto:[email protected]

  • V.Michaud, BPharm., PhD. C.V. Feb 2019

    2

    Educational Background

    1997/09 – 2001/05 B.Sc. Pharmacy, Faculté de Pharmacie, Université Laval, Ste-Foy, Québec.

    2001/09 – 2003/12 M.Sc., Faculté de Pharmacie, Université de Montréal, Montreal, Quebec.

    2004/01 – 2009/01 Ph.D., Faculté de Pharmacie, Université de Montréal, Montreal, Quebec.

    2009/02 – 2010/04 Post-doctoral fellow, Faculty of medicine McGill University, Montreal, Quebec 2010/05 – 2012/04 Post-doctoral fellow, School of medicine Indiana University, Indianapolis, Indiana, USA

    2011/09 – 2012/05 NIH course Principles of clinical pharmacology formation.

    2016/10 APhA Delivering Medication Therapy Management Services; MTM Services, Jefferson University, Philadelphia, PA

    2017/04 The Actionable Analytics for Risk Stratification Summit. Financial Research Associates LLC. La Jolla, CA Awards and Distinctions

    2001/09 – 2004/12 MDS Pharma Services Studentship Award.

    2004/03 – 2007/03 Rx&D Health Foundation Studentship Award (declined).

    2004/03 – 2008/03 CIHR Undergraduate Scholarship.

    2008/07 AFPC Future Academic Leader Award.

    2008 (Term; 2 years) FRSQ Fellowship Scholarship (declined).

    2009/05 FESP Dean Honour List.

    2009/02 – 2012/02 CIHR Fellowship Scholarship.

    2009/02 – 2012/02 Bisby Fellows Award.

    2010/06 William Mahon Trainee Presentation Award.

    2014/09 – 2018/08 Research Scholarship Junior 1 FRQ-S in partnership with INESSS.

  • V.Michaud, BPharm., PhD. C.V. Feb 2019

    3

    Research Experience

    2001/09 – 2003/12 Maîtrise ès Sciences Pharmacy

    Faculté de Pharmacie, Université de Montréal Montreal, Canada L’utilisation de la dompéridone comme substrat marqueur de l’activité in vitro des CYP3A4 et CYP3A5. Director: Jacques Turgeon, B.Pharm., Ph.D.

    2004/01 – 2009/01 Philosophiae Doctor Pharmacy

    Faculté de Pharmacie, Université de Montréal Montreal, Canada Étude in vitro et in vivo évaluant le rôle du métabolisme des

    médicaments par les CYP450s comme facteurs de variabilité interindividuelle dans la réponse aux médicaments.

    Director: Jacques Turgeon, B.Pharm., Ph.D. *The jury ranked my thesis in the top 5th percentile % of theses presented at the University of Montreal.

    2009/02 – 2010/04 Post-doctoral fellow

    Lady Davis Institute, McGill University. Montreal, Canada Supervisor: Mark Wainberg, B.Sc., Ph.D.

    2010/05 – 2012/04 Post-doctoral fellow Division of Clinical Pharmacology, School of medicine, Indiana University. Indianapolis, IN, USA

    Supervisors: David Flockhart, MD, Ph.D. and Zeruesenay Desta, B.Pharm., Ph.D.

    Professional Experience

    2001/09 – 2002/05 Pharmacist, Pharmacie Jean Coutu Sonia Guimont.

    2002/05 – 2006/12 Pharmacist, Pharmacie Pascal Monarque & Christian DeBlois.

    2007/01 – 2007/03 Pharmacist, Pharmacie Jacques Meilleur.

  • V.Michaud, BPharm., PhD. C.V. Feb 2019

    4

    Teaching Experience

    2002–2009 CYP450 and Drug-drug interactions (PHM6508). 2008–2009 Pain pharmacology; Pharmacogenetics. (PHL6035). 2007–2008 Pharmacology 2; Pharmacology of analgesic drugs (PHM3235). 2009 Managing end-of-life symptoms; Drug-drug interactions in palliative

    care (PAL6110).

    2010/06 Symposium on pharmacogenetics and cardiovascular disease. Third International Meeting on Pharmacy and Pharmaceutical Sciences. Istanbul, Turkey.

    The influence of pharmacogenetics for warfarin dose requirements.

    2011/04 Certificate program of predictive and personalized medicine in daily

    medical practice. Yeditepe University, Faculty of medicine and Faculty of pharmacy. Istanbul, Turkey. The role of pharmacogenetics for cardiovascular drug effects. A special look at warfarin and clopidogrel.

    2011–2016 Pharmacokinetics and Formulation II; Pharmacokinetics applied for

    special populations, Pharmacogenetics (SBP2040).

    2012–2016 Biopharmacy Pharmacokinetics; Drug transport, Bioavailability, Pharmacokinetics for special populations (PHM6506).

    2012–2015 Drug development; Pharmacogenetics (PHM6110).

    2013–2016 Pharmacokinetics and Formulation I; Transporters and Bioavailability (SBP2030).

    2013–2015 Advanced pharmaceutical care Gastroenterology;

    Pharmacokinetics and liver diseases (PAP1120).

    2013/11 Review of pharmacokinetics in small intestine; drug absorption and metabolism (residents in gastroenterology) (GAS8000).

    2014–2016 Pharmacokinetics and Formulation 1; Route of drugs in the body,

    Drug metabolism (SBP2030).

    2014–2015 Biopharmacy Pharmacokinetics; Metabolism of drugs (PHM6506)

    2017/02 Pharmacogenomics; Drug Transporters (PP541) College of Pharmacy, University of Sciences, Philadelphia, PA 2018/09-12 Pharmacogenetics of Drug metabolism and Transport (PHA6427) College of Pharmacy, University of Florida, Gainesville, FL

  • V.Michaud, BPharm., PhD. C.V. Feb 2019

    5

    Educational Involvement 2014–2016 Member, Review Committee A, Doctoral Research Award, Canadian

    Institute of Health Research.

    2014–2016 Member, Comité conjoint de la Faculté de Pharmacie, Université de

    Montréal

    2014/02 Member, Review Committee, Ph.D. scholarship, Montreal diabetes

    Research Center.

    2015–2016 Member, Review Committee, Ph.D. scholarship, Fonds de Recherche

    du Quebec en Santé

    2015–2016 Member, CMDP, CHUM

    2015–2016 Member, Pedagogic Committee, QeP program, Faculty of Pharmacy,

    Université de Montréal

    2015–2016 Member, Admission Committee, QeP program, Faculty of Pharmacy,

    Université de Montréal

    Professional Societies

    Ordre des Pharmaciens du Québec (No 201261) American Society for Clinical Pharmacology and Therapeutics International Society for the Study of Xenobiotics Canadian Society of Pharmacology and Therapeutics Montreal Diabetes Research center

    Research and/or professional activities outside institution

    2006 – 2016 Shareholder of InterMED-Rx

    2014 – 2018 Consultant; Pharmacokinetic expert for Institut national d’excellence

    en santé et en service sociaux (INESSS)

  • V.Michaud, BPharm., PhD. C.V. Feb 2019

    6

    Presentation as guest speaker

    2018/09/23 International Congress on Personalized Health Care 2018. Conference entitled; Impact of GSTA1 polymorphisms on the oral

    clearance of busulfan in adult patients undergoing hematopoietic stem cell transplantation.

    Montreal, Canada 2018/08/18 2018 PCS 4th Global Pain Conference Conference entitled; Pain management pharmacotherapy in the

    context of polypharmacy and drug-drug interactions. Florence, Italy 2018/07/16 International Conference on Diabetes, Endocrinology and Metabolism Conference entitled; The impact of type 2 diabetes on CYP450 drug

    metabolism capacity. Prague, Czech Republic 2018/03/21 Lake Nona Leadership Council VII Center for Pharmacometrics and systems pharmacology, Research and Academic Center at Lake Nona Conference entitled; CYP450 phenoconversion in patients with type 2

    diabetes: a mechanism for variability in drug response. Orlando, Florida 2016/12/05 Center for Pharmacometrics and systems pharmacology, Research and Academic

    Center at Lake Nona, University of Florida. Conference entitled; Intersubject variability in drug response; Role of

    hepatic and extra-hepatic CYP450s. Orlando, Florida 2016/04/01 CHUM Endocrinology department meeting. Conference entitled; Drug metabolism in patients with type 2

    diabetes. Montreal, Quebec. 2012/07/04 4th Summer School on Medicines (SSM4) Conference entitled; Basic concepts in pharmacokinetics. Montreal, Quebec. 2012/04/21 15th Annual conference of the Association Médicale du Québec

    Conference entitled; La Médecine Prédictive et Personnalisée. Montreal, Quebec.

  • V.Michaud, BPharm., PhD. C.V. Feb 2019

    7

    2012/04/17 Certificate Program of Predictive and Personalized Medicine in Daily Medical Practice.

    Conference entitled; The role of pharmacogenetics for cardiovascular drug effects. A special look at warfarin and clopidogrel. Yeditepe University, Istanbul, Turkey.

    2010/06/10 Third International Meeting on Pharmacy and Pharmaceutical

    Sciences. Symposium on Pharmacogenetics and Cardiovascular diseases. Conference entitled; The influence of PGx for warfarin dose

    requirements. Istanbul, Turkey. 2005/09 Scientific conference at the Geriatric Institute of Montreal

    Conference entitled; Les interactions médicamenteuses dans le traitement de la douleur. Sponsored by Janssen Ortho Canada.

    Montreal, Quebec.

    2004/12 Interdisciplinary formation meeting on opioid dependence/abuse. Mechanisms of drug-drug interactions with CYP450s and intersubject variability in drug-response. Montreal, Quebec.

  • V.Michaud, BPharm., PhD. C.V. Feb 2019

    8

    Research Funding History

    2014/09 – 2018/08 Research Scholar-Junior 1 FRQ-S in partnership with INESSS stopped 2016/09 Intersubject variability in drug response; role of extra-hepatic drug

    metabolism, physiopathologic conditions and pharmacogenetics. Total funding; $303,086

    2014/09 – 2017/08 Starting grant for young investigator Junior 1 from Fonds de

    Recherche du Québec en santé (FRQ-S). Total funding; $60,000

    2014/06 – 2015/12 Canadian Foundation for Innovation (CFI)

    CFI Leader Opportunity Funds Research infrastructure. CYP450 expression and activity quantification platform.

    Principal investigator; Veronique Michaud Total funding; $287,500

    2014/06 – 2018/05 Fonds Québécois de la Recherche sur la Nature et les et les

    Technologies (FQRNT) Synthèse stéréosélective d'arylcyclopropyléthers et étude de leur stabilité métabolique en presence de cytochromes P450. Principal investigator; Andre Charette

    Co-investigators; Alexandre Gagnon, Veronique Michaud Total funding; $48,000 2014/02 – 2015/01 Diabetes Quebec and Montreal Diabetes Research Center

    Pilot grant Principal investigator; Veronique Michaud Total funding; $10,000

    2014 – 2018 Ministère des Finances et de l’Économie. Fonds de stopped by the Minister 2017 partenariat pour un Québec innovant.

    Optimisation des approches thérapeutiques en soins de première ligne : OPTI-THERA

    Principal Investigators: Pavel Hamet, Jacques Turgeon Co-applicants: Johanne Tremblay, Veronique Michaud,

    Janusz Kaczorowski, Jean Lachaine, Bartha Knoppers Lyne, Lalonde, Philippe Awadalla

    Total funding; $18,374,984

  • V.Michaud, BPharm., PhD. C.V. Feb 2019

    9

    2013/10 – 2017/09 Canadian Institutes of Health Research (CIHR)

    Effects of Type 2 Diabetes (T2D) on drug disposition and CYP450 activities; a special look at extra-hepatic metabolism.

    Principal investigator; Veronique Michaud Co-investigators: Jean-Louis Chiasson, Vincent Poitout, and Pavel

    Hamet Total funding; $507,268

    2012/04 – 2017/03 Canadian Institutes of Health Research (CIHR)

    The first characterization of functional CYP450 activities in human cardiac myocytes: Modulation of cardiac potassium channel block due to local metabolism of QT-prolonging drugs. Principal investigator; Jacques Turgeon

    Co-investigators: Veronique Michaud, Benoit Drolet, and Chantal Simard Total funding; $807,020

    2012/07 – 2015/06 Heart and Stroke Foundation of Canada (HSFC)

    The first characterization of functional CYP450 activities in human cardiac myocytes. Principal investigator; Jacques Turgeon

    Co-investigators: Veronique Michaud, Benoit Drolet, and Chantal Simard

    Total funding; $60,000

    2012/06 – 2013/05 Rx & D Health Research Foundation Effects of type 2 diabetes on expression and activities of CYP450 drug metabolizing enzymes Principal investigator; Veronique Michaud

    Total funding; $25,000

    2018/01 – 2018/12 Establishment funds College of Pharmacy, University of Florida

    Total funding; $500,000 Principal investigator; Veronique Michaud

  • V.Michaud, BPharm., PhD. C.V. Feb 2019

    10

    2017 – Palliative Care Research Consortium and Tabula Rasa Healthcare Co-sponsorship ($500 000)

    A Prospective Multicenter Cohort Study to Evaluate the Characteristics and Clinical Implications of Pharmacogenomic Information Relevant to Polypharmacy Actions in Patients with Advanced Illness Who Are Receiving Multiple Drugs for Pain and Other Disorders.

    Co-investigators: Janet Bull, Russell Portenoy, Veronique Michaud, Kevin Bain, and Jacques Turgeon

  • V.Michaud, BPharm., PhD. C.V. Feb 2019

    11

    Supervision of Graduate Students

    09/2013 – Sophie Gravel, M.Sc./Ph.D. in Pharmaceutical Sciences

    01/2013 – 2018/08 Yat Hei Leung, Ph.D. in Pharmaceutical Sciences

    2015/05 – 2018/01 Valerie Clermont, M.Sc. in Pharmaceutical Sciences

    2013/01 – 2017/06 Jennifer Lu, Ph.D. in Pharmaceutical Sciences

    2014/08 – 2017/02 Sarah Maximos, MD-M.Sc. in Biomedical Sciences

    2014/09 – 2017/05 Alexia Grangeon, M.Sc. in Pharmaceutical Sciences

    2015/09 – 2016/08 Roxanne Pelletier, M.Sc. in Pharmaceutical Sciences Supervision of PharmD student to M.Sc. Residency to pharmacotherapy program

    2012/06 – 2012/12 Candidates; Maude Beauchamp-Vien, Émilie Boisvert, Ann-Sophie Payette, Alessandra Stortini Co-supervisor (scientific director)

    Project; Evaluation of the relationship between Acid mycophenolique (MyforTIC®) drug exposure and adverse drug reactions in stable kidney transplant patients.

    2012/09 – 2013/12 Candidates; Benoit Crevier, Sami Suhail Jiouni, Jennifer Yee Co-supervisor (scientific director) Project; QTVIE study 2013/09 – 2014/12 Candidates; Yvonne Yeung, Mohammad El-Sakkary, Hao Wang, Ngan Zinquon Scientific director Project; Candy study Supervision of Undergraduate Students

    2013/05 – 2013/08 Kathryn Chadwick, B.Sc., Stage, Queen’s University

    2014/05 – 2014/09 Nour Ghazal, B.Sc. in Pharmaceutical Sciences, UdM

    2014/05 – 2014/09 Roxanne Pelletier, B.Sc. in Pharmaceutical Sciences, UdM

    2015/05 – 2015/09 Michel Chamoun, B.Sc. in Pharmaceutical Sciences, UdM

    2015/05 – 2015/09 Charles Hosmi, B.Sc. in Pharmaceutical Sciences, UdM 2018/05 – 2018/12 My Tran, PharmD, College of Pharmacy, UF

  • V.Michaud, BPharm., PhD. C.V. Feb 2019

    12

    Detailed Publications

    Published refereed papers

    1) Michaud V, Turgeon J. Cytochrome P450, drug interactions and the treatment of dementia. Geriatrics and Aging 2003; 6(2):22-7.

    2) Simard C, Michaud V, Gibbs B, Massé R, Lessard E, Turgeon J. Identification of the cytochrome P450 enzymes involved in the metabolism of domperidone. Xenobiotica 2004; 34(11/12):1013-23.

    3) Turgeon J, Pharand C, Michaud V. Understanding clopidogrel efficacy in the presence of cytochrome

    P450 polymorphism. Commentary, Canadian Medical Association Journal 2006; 174(12)1729-30. 4) Michaud V, Mouksassi M-S, Labbé L, Bélanger P-M, Lefebvre M, Gilbert M, Grech-Bélanger O,

    Turgeon J. Inhibitory effects of propafenone on the pharmacokinetics of caffeine in man. Therapeutic Drug Monitoring 2006; 28(6):779-83.

    5) Michaud V, Simard C, Turgeon J. An improved HPLC assay with fluorescence detection for the determination of domperidone and three major metabolites for application to in vitro drug metabolism studies. J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Jun 1;852(1-2):611-6.

    6) Michaud V, Vanier MC, Brouillette D, Roy D, Verret L, Noël N, Taillon I, O’Hara G, Gossard D,

    Champagne M, , Goodman K, Renaud Y, Brown A, Phillips M, Ajami A., Turgeon. Combination of phenotype assessments and CYP2C9-VKORC1 polymorphisms in the determination of warfarin dose requirements in heavily medicated patients Clin Pharmacol Ther. 2008 May; 83(5):740-8.

    7) Fenneteau F, Turgeon J, Couture L, Michaud V, Li J, Nekka F. Assessing drug distribution in tissues

    expressing P-glycoprotein through physiologically based pharmacokinetic modelling: model structure and parameters determination. Theor Biol Med Model. 2009 Jan15; 6:2.

    8) Michaud V, Simard C, Turgeon J. Characterization of CYP3A Isozymes involved in the Metabolism of

    Domperidone : role of Cytochrome b5 and inhibition by ketoconazole. Drug Metab Lett. 2010 Apr 1; 4(2): 95-103.

    9) Michaud V, Turgeon J. Assessement of competitive and mechanism-based inhibition by

    clarithromycin: use of domperidone as a CYP3A probe-drug and various enzymatic sources including a new cell-based assay with freshly isolated human hepatocytes. Drug Metab Lett. 2010 Apr 1; 4(2): 69-76.

    10) Bar-Magen T, Donahue D.A, McDonough E, Kuhl B.D, Faltenbacher V.H, Xy H, Michaud V, Sloan R.D,

    Wainberg M.A. HIV-1 subtype B and C integrase enzymes exhibit differential patterns of resistance to integrase inhibitors in biochemical assays. AIDS. 2010 Sep; 24(14): 2171-9.

  • V.Michaud, BPharm., PhD. C.V. Feb 2019

    13

    Published refereed papers (continued) 11) Michaud V, Dumas M-C, Frappier M, Turgeon J. Determination of relative levels of human cardiac

    CYP450 isoforms in patients with heart failure. PLoS One 2010; 5(12):e15666. 12) O’Hara G, Philippon F, Gilbert M, Champagne J, Michaud V, Charbonneau L, Pruneau G, Hamelin B.A,

    Geelen P, and Turgeon J. Combined Administration of Quinidine and Propafenone for Atrial Fibrillation: The CAQ-PAF Study. J Clin Pharmacol. 2011 Apr 20; 52(2):171-9 (EPub).

    13) Michaud V, Turgeon J, Flockhart D, Wainberg M. Rôle de la pharmacogénétique dans la réponse au

    traitement antirétroviral de l’infection par le VIH. Virologie 2011; 15 (3) :157-74. 14) Michaud V, Ogburn E, Kreutz Y , Thong N, Aregbe AO., Quigg TC., Epstein N, Callaghan JT., Flockhart

    DA., Desta Z. Induction of CYP2C19 and CYP3A activities following repeated administration of efavirenz in human. Clin Pharmacol Ther. Mar 2012; 91 (3):475-82.

    15) Michaud V, Bar-Magen T, Turgeon J, Desta Z, Flockhart D, Wainberg M. The dual role of

    pharmacogenetics in HIV treatment: Mutations and polymorphisms regulating antiretroviral drug resistance and disposition. Pharmacol Rev.2012; 64 (3):803-33.

    16) Michaud V, Turgeon J. Domperidone and sudden cardiac death: how much longer should we wait? J

    Cardiovasc Pharmacol. 2013 Mar; 61(3):215-7.

    17) Skrobik Y, Leger C, Cossette M, Michaud V, Turgeon J. Factors Predisposing to Coma and Delirium: Fentanyl and Midazolam Exposure, CYP3A5, ABCB1 and ABCG2 Genetic Polymorphisms, and Inflammatory Factors. Cri Care Med. 2013 Apr; 41(4):999-1008.

    18) Michaud V, Kreutz Y , Skaar T, Ogburn E, Thong N, Flockhart DA., Desta Z. Induction of omeprazole

    metabolism by efavirenz as a function of CYP2C19 genotype. Pharmacogenomics J 2013; Apr30: 1-9 (Epub).

    19) Madadi P, Amstutz U, Rieder M, Ito S, Fung V, Hwang S, Turgeon J, Michaud V, Koren G, Carleton

    BC; CPNDS Clinical Recommendations Group. Clinical practice guideline: CYP2D6 genotyping for safe and efficacious codeine therapy. J Popul Ther Clin Pharmacol 2013; 20(3):e369-96.

    20) Lu J, Michaud V, Guilarta Moya L, Gaudette F, Leung YH, Turgeon J. Effects of β-blockers and tricyclic

    antidepressants on the activity of human organic anion transporting polypeptide 1A2 (OATP1A2). JPET 2015; 352(3):552-8

    21) Shaw K, Amstutz U, Kim R, Lawrence Lesko J.L, Rhoades J, Turgeon J, Michaud V, Hwang S, Ito S,

    Carleton B., and the CPNDS clinical recommendation group. Clinical Practice Recommendations on Genetic Testing of CYP2C9 and VKORC1 variants in Warfarin Therapy. Ther Drug Monit 2015.

    http://www.ncbi.nlm.nih.gov/pubmed?term=Madadi%20P%5BAuthor%5D&cauthor=true&cauthor_uid=24214521http://www.ncbi.nlm.nih.gov/pubmed?term=Amstutz%20U%5BAuthor%5D&cauthor=true&cauthor_uid=24214521http://www.ncbi.nlm.nih.gov/pubmed?term=Rieder%20M%5BAuthor%5D&cauthor=true&cauthor_uid=24214521http://www.ncbi.nlm.nih.gov/pubmed?term=Ito%20S%5BAuthor%5D&cauthor=true&cauthor_uid=24214521http://www.ncbi.nlm.nih.gov/pubmed?term=Fung%20V%5BAuthor%5D&cauthor=true&cauthor_uid=24214521http://www.ncbi.nlm.nih.gov/pubmed?term=Hwang%20S%5BAuthor%5D&cauthor=true&cauthor_uid=24214521http://www.ncbi.nlm.nih.gov/pubmed?term=Turgeon%20J%5BAuthor%5D&cauthor=true&cauthor_uid=24214521http://www.ncbi.nlm.nih.gov/pubmed?term=Koren%20G%5BAuthor%5D&cauthor=true&cauthor_uid=24214521http://www.ncbi.nlm.nih.gov/pubmed?term=Carleton%20BC%5BAuthor%5D&cauthor=true&cauthor_uid=24214521http://www.ncbi.nlm.nih.gov/pubmed?term=Carleton%20BC%5BAuthor%5D&cauthor=true&cauthor_uid=24214521http://www.ncbi.nlm.nih.gov/pubmed?term=CPNDS%20Clinical%20Recommendations%20Group%5BCorporate%20Author%5Dhttp://www.ncbi.nlm.nih.gov/pubmed/24214521

  • V.Michaud, BPharm., PhD. C.V. Feb 2019

    14

    Published refereed papers (continued)

    22) Gaudette F, Sirhan-Daneau A, St-Onge M, Turgeon J, Michaud V. Development of a sensitive method for the determination of oxycodone and its major metabolites noroxycodone and oxymorphone in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Jan 1;1008:174-80

    23) Bouchard P, Bilodeau S, Alain K, Vadnais B, Franco M, Turgeon J, Michaud V. Evaluation of limited

    sampling methods for oral busulfan pharmacokinetic monitoring in adult patients undergoing hematopoietic stem cell transplantation. Ther Drug Monit. 2016; 38(3):414-8.

    24) Turgeon J, Michaud V. Clinical decision support systems: Great promises for better management of patients' drug therapy. Expert Opin Drug Metab Toxicol. 2016; 72 (8):925-31.

    25) Huguet J, Lu J, Gaudette F, Chiasson JL, Hamet P, Michaud V, Turgeon J. No Effects of pantoprazole on

    the pharmacokinetics of rosuvastatin in healthy subjects. Eur J Pharmacol 2016; 72(8):925-31.

    26) Lu J, Grangeon A, Gaudette F, Turgeon J, Michaud V. Effects of tricyclic compounds on the transport of anti-migraine triptans through human organic anion transporting polypeptide 1A2 (OATP1A2). J Pharmacokinet Exp Ther 2016; 1(2):1-11.

    27) Grangeon A, Gravel S, Gaudette F, Turgeon J, Michaud V. Highly sensitive LC-MS/MS methods for the

    determination of seven human CYP450 activities using small oral doses of probe-drugs in human. J Chromatogr B Analyt Technol Biomed Life Sci. 2017; 1040:144-58.

    28) Turgeon J, Michaud V, Steffen L. The dangers of polypharmacy in elderly patients. Letter to the Editor:

    Polypharmacy in the Elderly- when good drugs lead to bad outcomes. A teachable moment (April 24, 2017; E1). JAMA Internal Med 2017;177(10):1544

    29) Maximos S, Chamoun M, Gravel S, Turgeon J, Michaud V. Tissue Specific Modulation of cyp2c and cyp3a mRNA Levels and Activities by Diet-Induced Obesity in Mice: The Impact of Type 2 Diabetes on Drug Metabolizing Enzymes in Liver and Extra-Hepatic Tissues. Pharmaceutics 2017 Sep 26;9(4).

    30) Leung YH, Turgeon J, Michaud V. Study of Statin- and Loratadine-Induced Muscle Pain Mechanisms Using Human Skeletal Muscle Cells. Pharmaceutics 2017 Oct 10;9(4).

    31) Huguet J, Gaudette F, Michaud V, Turgeon J.Development and validation of probe drug cocktails for the characterization of CYP450-mediated metabolism by human heart microsomes. Xenobiotica 2018 Feb 16:1-46.

    32) Gravel S, Chiasson JL, Dallaire S, Turgeon J, Michaud V. Evaluating the impact of type 2 diabetes mellitus on CYP450 metabolic activities: protocol for a case-control pharmacokinetic study. BMJ Open 2018 Feb 8;8(2).

    33) Leung YH, Lu J, Belanger F, Turgeon J, Michaud V. Effects of a series of acidic drugs on L-lactic acid transport by the monocarboxylate transporters MCT1 and MCT4. Current Pharmaceutical Biotechnology. 2018;18(14):1141-50.

    http://www.ncbi.nlm.nih.gov/pubmed/26829598http://www.ncbi.nlm.nih.gov/pubmed/26829598http://www.ncbi.nlm.nih.gov/pubmed/26829598http://www.ncbi.nlm.nih.gov/pubmed/27021287http://www.ncbi.nlm.nih.gov/pubmed/27021287https://www.ncbi.nlm.nih.gov/pubmed/27978469https://www.ncbi.nlm.nih.gov/pubmed/27978469https://www.ncbi.nlm.nih.gov/pubmed/28954402https://www.ncbi.nlm.nih.gov/pubmed/28954402https://www.ncbi.nlm.nih.gov/pubmed/28954402https://www.ncbi.nlm.nih.gov/pubmed/28994701https://www.ncbi.nlm.nih.gov/pubmed/28994701https://www.ncbi.nlm.nih.gov/pubmed/29448869https://www.ncbi.nlm.nih.gov/pubmed/29448869

  • V.Michaud, BPharm., PhD. C.V. Feb 2019

    15

    34) Cicali B, Michaud V, Knowlton HK, and Turgeon J. 2018. Application of a novel medication-related risk stratification strategy to a self-funded employer populations. Benefits Quaterly. second quarter 2018:34; 49-55.

    35) Gaudette F, Hamadjida A, Bédard D, Nuara SG, Gourdon JC, Michaud V, Beaudry F, Huot P. Development of a selective and sensitive high-performance liquid chromatography-tandem mass spectrometry assay to support pharmacokinetics studies of LY-487,379 in rat and marmoset. J Chromatogr B Analyt Technol Biomed Life Sci 2018: 1093-94:1-7.

    36) Huguet J, Gaudette F, Michaud V, Turgeon J. Development and validation of probe drug cocktails for the characterization of CYP450-mediated metabolism by human heart microsomes. Xenobiotica 2019;49(2):187-99.

    37) Clermont V, Grangeon A, Barama A, Lallier M, Malaise J, Turgeon J, Michaud V. Activity and mRNA

    expression levels of selected cytochrome P450s in various sections of the human small intestine. Br J

    Clin Pharmacol. Accepted 2019

    Submitted refereed papers

    1) Grangeon A, Clermont V, Barama A, Gaudette F, Turgeon J, Michaud V. Development and validation

    of an absolute protein assay for the simultaneous quantification of fourteen CYP450s in human microsomes by LC-MS/MS-based targeted proteomics. J Pharmaceut Biomed Analyt Submitted Jan 2019.

    2) Gravel S, Chiasson JL, Turgeon J, Grangeon A, Michaud V. Modulation of CYP450 activities in patients with type 2 diabetes. Clin Pharmacol Ther. Submitted Jan 2019.

    3) Gravel S, Gaudette F, Chiasson JL, Turgeon J, Michaud V. Use of 4-hydroxycholesterol plasma concentrations as an endogenous biomarker of CYP3A activity: Clinical validation in patients with Type 2 diabetes. Clin Pharmacol Ther. Submitted Feb 2019.

    4) Yeung YF, Hao W, Zinquon N, El-Sakkary M, Landry S, Michaud V, Ghazal N, Gaudette F, Hetu P-O, Lebouche B, Sheehan N. Atazanavir, Darunavir and Tenofovir Concentrations in Subjects with HIV and Type 2 diabetes mellitus – a pilot study. JAC. Submitted.

    Published contributions to a collective work and book chapters 1) Hreiche R, Michaud V, Turgeon J. Chapter 3 - The role of ethnicity in managing cardiovascular

    patients. In; “Cardiovascular genetics and genomics” Edited by Dan M. Roden. 2009; 33-46.

    2) Michaud V. Étude in vitro et in vivo évaluant le rôle du métabolisme des médicaments par les CYP450s comme facteurs de variabilité interindividuelle dans la réponse aux médicaments. Faculté

    https://www.ncbi.nlm.nih.gov/pubmed/29448869https://www.ncbi.nlm.nih.gov/pubmed/29448869https://www.ncbi.nlm.nih.gov/pubmed/29448869

  • V.Michaud, BPharm., PhD. C.V. Feb 2019

    16

    des Études Supérieures de l’Université de Montréal. Les Presses de l’Université de Montréal; PhD. Thesis : 2009.

    3) Maximos S, Chamoun M, Gravel S, Turgeon J, Michaud V. In Pharmacokinetics and Drug metabolism

    in Canada : The current landscape. Chapter; Tissue Specific Modulation of cyp2c and cyp3a mRNA Levels and Activities by Diet-Induced Obesity in Mice: The Impact of Type 2 Diabetes on Drug Metabolizing Enzymes in Liver and Extra-Hepatic Tissues. MDPI 2018; 174-191.

    4) Leung YH, Turgeon J, Michaud V. In Pharmacokinetics and Drug metabolism in Canada : The current

    landscape. Chapter; Study of Statin- and Loratadine-Induced Muscle Pain Mechanisms Using Human Skeletal Muscle Cells. MDPI 2018; 161-73.

    https://www.ncbi.nlm.nih.gov/pubmed/28954402https://www.ncbi.nlm.nih.gov/pubmed/28954402https://www.ncbi.nlm.nih.gov/pubmed/28954402https://www.ncbi.nlm.nih.gov/pubmed/28954402https://www.ncbi.nlm.nih.gov/pubmed/28954402https://www.ncbi.nlm.nih.gov/pubmed/28954402

  • V.Michaud, BPharm., PhD. C.V. Feb 2019

    17

    Published abstracts 1) Michaud V, Simard C, Turgeon J. L’utilisation de la dompéridone comme substrat marqueur de

    l’activité des CYP3A4 et CYP3A5. Congrès du Club de Recherche Clinique du Québec 2002. Médecine Science 2002;18(2):28.

    2) Michaud V, Simard C, Massé R, Turgeon J. Domperidone as a substrate marker drug for CYP3A4 and

    CYP3A5. American Society for Clinical Pharmacology and Therapeutics 2003. Clin Pharmacol Ther 2003;73(2):47.

    3) Michaud V, Simard C, Massé R, Turgeon J. Domperidone as a probe drug for CYP3A4 and CYP3A5.

    Association of Faculties of Pharmacy of Canada and Canadian College of Clinical Pharmacy 2003. 4) Michaud V, Simard C, Massé R, Turgeon J. A search for a substrate marker drug for CYP3A4 and

    CYP3A5: Domperidone. Canadian Society for Clinical Pharmacology 2003. Can J Clin Pharmacol 2003;10(3):152.

    5) Michaud V, Morin N, Brouillette D, Roy D, Verret L, Noel N, Taillon I, O’Hara G, Gossard D,

    Champagne M, Vanier M-C, Turgeon J. Génotype ou Phénotype? Leur rôle dans l’individualisation de traitement pour des agents cardiovasculaires. Congrès du Club de Recherche Clinique du Québec 2003. Médecine Science 2003;19(2):18.

    6) Michaud V, Morin N, Brouillette D, Roy D, Verret L, Noel N, Taillon I, O’Hara G, Gossard D,

    Champagne M, Vanier M-C, Turgeon J. Genotype or Phenotype? Role of these strategies for individualized therapy for cardiovascular drugs patients. Canadian Cardiovascular Society 2003. Can J Cardiol 2003;19(Suppl A):171-2.

    7) Michaud V, Morin N, Brouillette D, Roy D, Verret L, Noel N, Taillon I, O’Hara G, Gossard D,

    Champagne M, Vanier M-C, Turgeon J. Comparative genotypic and phenotypic strategies for individualized therapy with warfarin. American Society for Clinical Pharmacology and Therapeutics 2004. Clin Pharmacol Ther 2004; 75(2):P60.

    8) Michaud V, Brouillette D, Roy D, Verret L, Noel N, Taillon I, O’Hara G, Gossard D, Champagne M,

    Vanier MC, Turgeon J. Phenotypic strategies, a better approach for individualized warfarin therapy. Association of Faculties of Pharmacy of Canada and Canadian College of Clinical Pharmacy 2004.

    9) Michaud V, Harvey M, Goodman K, Morin N, Brouillette D, Roy D, Verret L, Noël N, Taillon I, O’Hara

    G, Gossard D, Champagne M, Rosati A, Vanier MC, Ajami A, Turgeon J. Warfarin as its own phenotypic probe drug: nomogram for dose prediction in patients. International congress of Clinical Pharmacology and Therapeutics Brisbane 2004.

    10) Michaud V, Harvey M, Goodman K, Pastinen T, Phillips M S., Morin N, Brouillette D, Roy D, Verret L,

    Noël N, Taillon I, O’Hara G, Gossard D, Champagne M, Vanier MC, Ajami A, Turgeon J. Polymorphismes du CYP2C9 et de VKOR dans l’établissement d’un nomogramme de traitement pour la warfarine. Congrès du Club de Recherche Clinique du Québec 2004. Médecine Science 2004.

  • V.Michaud, BPharm., PhD. C.V. Feb 2019

    18

    Published abstracts (continued) 11) Michaud V, Massé R, Turgeon J. CYP2J2 metabolizes domperidone in guinea pig hearts. American

    Society for Clinical Pharmacology and Therapeutics 2005. Clin Pharmacol Ther 2005; 77(2):P75 12) Michaud V, Mouksassi M-S, Labbé L, Bélanger P-M, Lefebvre M, Gilbert M, Grech-Bélanger O,

    Turgeon J. Effet inhibiteur de la propafénone sur l’élimination de la caffeine. Congrès du Club de Recherche Clinique du Québec 2005. Médecine Science 2005; 21(suppl 2) :33.

    13) Michaud V, Mouksassi M-S, Labbé L, Bélanger P-M, Lefebvre M, Gilbert M, Grech-Bélanger O,

    Turgeon J. Effects of propafenone on the pharmacokinetics of caffeine. American Society for Clinical Pharmacology and Therapeutics 2006. Clin Pharmacol Ther 2006; 79(2):21.

    14) Michaud V, Massé R, Turgeon J. Inhibitory potency of clarithromycin towards CYP3As. American

    Society for Clinical Pharmacology and Therapeutics 2006. Clin Pharmacol Ther 2006; 79(2):77. 15) Michaud V, Turgeon J. Potentiel inhibiteur de la clarithromycine et CYP3As. Congrès du Club de

    Recherche Clinique du Québec 2006. Médecine Science 2006; 22(2):139. 16) Michaud V, Harvey M, Goodman K, Morin N, Brouillette D, Roy D, Verret L, Noël N, Taillon I, O’Hara

    G, Gossard D, Champagne M, Rosati A, Vanier MC, Ajami A, Simard S, Turgeon J. Polymorphisms in VKOR and phenotype of CYP2C9 contribute to inter-individual variability of warfarin. Canadian Cardiovascular Society 2006. Can. J. Cardiol. 2006, 22(Suppl D):223.

    17) Michaud V, Harvey M, Goodman K, Morin N, Brouillette D, Roy D, Verret L, Noël N, Taillon I, O’Hara

    G, Gossard D, Champagne M, Rosati A, Vanier MC, Phillips M, Ajami A, Turgeon J. CYP2C9 phenotype and CYP2C9 and VKORC1 genotypes as modulatory factors of warfarin effects in Caucasian patients with multiple drug regimen. American Society for Clinical Pharmacology and Therapeutics 2007. Clin Pharmacol Ther 2007;81(supp1):S92.

    18) Michaud V, Vanier M-C, Brouillette D, Roy D, Verret L, Noel N, Taillon I, O’Hara G, Gossard D,

    Champagne M, Goodman K, Renaud Y, Brown A, Phillips M, Ajami A M, Turgeon J. CYP2C9 and VKORC1 polymorphisms combined to phenotypic assessments: their role in warfarin dose requirements in a hospitalized, heavily medicated patient population. Human Genome Meeting 2007. P237.

    19) Michaud V, Vanier M-C, Brouillette D, Roy D, Verret L, Noel N, Taillon I, O’Hara G, Gossard D,

    Champagne M, Goodman K, Renaud Y, Brown A, Phillips M, Ajami A M, Turgeon J. The role of CYP2C9 and VKORC1 polymorphisms combined to CYP2C9 phenotypic assessments to explain intersubject variability in warfarin dose requirements in a hospitalized, heavily medicated patient population. Canadian Society of Clinical Pharmacology 2007. CSCP oral presentation. P132; 43.

  • V.Michaud, BPharm., PhD. C.V. Feb 2019

    19

    Published abstracts (continued) 20) Bouchard P, Bilodeau S, Alain K, Vadnais B, Franco M, Busque L, Roy D.C, Michaud V and Turgeon J.

    Impact of individual characteristics on oral Busulfan pharmacokinetics in adults patients undergoing hematopoietic stem-cell transplantation. American Society of Hematology. Blood 2007;110:1993.

    21) Michaud V, Pronovost B, Bouchard P, Alain K, Bilodeau S, Bélanger F, Roy CD, Busque L, Vadenais B,

    Turgeon J. Impact du polymorphisme de la GST-A1 sur le métabolisme du busulfan administré par voie orale lors d’une pré-greffe de moelle osseuse. Congrès du Club de Recherche Clinique du Québec 2007. Médecine Science 2007; 23(suppl 2) :12.

    22) Michaud V, Dumas M-C, Turgeon J. Le cœur, un organe doué d’activité métabolique envers le

    vérapamil. Congrès du Club de Recherche Clinique du Québec 2007. Médecine Science 2007; 23(suppl 2) :11.

    23) Hreiche R, Michaud V, Simard C, Turgeon J, Drolet B. L'effet du dofétilide sur la repolarisation

    cardiaque est module par la concentration de glucose et par la diète riche en sucrose. Congrès du Club de Recherche Clinique du Québec 2007. Médecine Science 2007; 23(suppl 2) :1.

    24) Hreiche R, Michaud V, Simard C, Turgeon J, Drolet B. Effects of glucose concentration on

    repolarization under conditions of drug-induced blokade of Ikr in guinea-pigs fed with a high sucrose diet. Canadian Cardiovascular Congress, Quebec, October 20-24, 2007.

    25) Michaud V, Pronovost B, Bouchard P, Alain K, Bilodeau S, Bélanger F, Roy CD, Busque L, Vadenais B,

    Turgeon J. Role of the GST-A1 single nucleotide polymorphisms in the metabolism of busulfan administered orally in patients undergoing bone marrow transplantation. The 8th International ISSX Meeting, Sendai, Japan, October 9-12, 2007.P66.

    26) Michaud V, Dumas M-C, Hreiche R, Turgeon J. Metabolism of verapamil in the heart. The 8th

    International ISSX Meeting, Sendai, Japan, October 9-12, 2007.P. 27) Michaud V, Dumas M-C, Turgeon J. CYP2C8 is involved in the metabolism of verapamil in human

    heart microsomes. American Society for Clinical Pharmacology and Therapeutics Meeting, Orlando, April 2-5, 2008. Clin Pharmacol Ther 2008;83(supp1):S34 (PI85).

    28) Michaud V, Turgeon J. Assessement of metabolic-intermediate complex formation by clarithromycin

    (CLAR) using the CYP3A probe drug domperidone (DOM) and freshly isolated and grown human hepatocytes. American Society for Clinical Pharmacology and Therapeutics Meeting, Orlando, April 2-5, 2008. Clin Pharmacol Ther 2008;83(supp1):S34 (PI84).

    29) Michaud V, Turgeon J. Determination of relative levels of human cardiac CYP450 isoforms in patients

    with heart failure. American Society for Clinical Pharmacology and Therapeutics Meeting, Orlando, April 2-5, 2008. Clin Pharmacol Ther 2008; 83(supp1):S33 (PI83).

  • V.Michaud, BPharm., PhD. C.V. Feb 2019

    20

    Published abstracts (continued) 30) Michaud V, St-Onge M, Sirhan-Daneau A, Turgeon J. Improved HPLC assay for quantitative analysis of

    oxycodone, oxymorphone and noroxycodone in human biologiocal fluids. American Society for Clinical Pharmacology and Therapeutics Meeting, Orlando, April 2-5, 2008. Clin Pharmacol Ther 2008; 83(supp1):S33 (PI82).

    31) Bouchard P, Bilodeau S, Alain K, Vadnais B, Franco M, Michaud V, Turgeon J. Evaluation of limited

    sampling methods for oral busulfan pharmacokinetic monitoring in adult patients undergoing hematopoietic stem cell transplantation. American Society for Clinical Pharmacology and Therapeutics Meeting, Orlando, April 2-5, 2008. Clin Pharmacol Ther 2008;83(supp1):S74 (PIII07).

    32) Tonietto E, Cuerrier S. Boyer M, Letarte N, Noël C, Michaud V, Turgeon J. Clinical impact of drug

    interactions with chemotherapy metabolized by CYP3As. American Society for Clinical Pharmacology and Therapeutics Meeting, Orlando, April 2-5, 2008. Clin Pharmacol Ther 2008;83(supp1):PII39

    33) Michaud V, Dumas M-C, Turgeon J. Domperidone and verapamil are metabolized by human heart

    microsomal fractions. International congress of Clinical Pharmacology and Therapeutics, Quebec, July 2008.

    34) Michaud V, Frappier M, Bélanger F, Turgeon J. Determination of mRNAs levels of cardiac CYP450s

    involved in the metabolism of drugs from a large cohort of heart failure patients. American Society for Clinical Pharmacology and Therapeutics Meeting, Washington, March 18-21, 2009.Clin Pharmacol Ther 2009;85(supp1): (PI13).

    35) Sirhan-Daneau A, Michaud V, St-Onge M, Turgeon J. Pharmacokinetics of oxycodone in extensive and

    poor metabolizers of CYP2D6 during co-treatment with placebo or quinidine. European ISSX Meeting, Lisbon, Portugal, May 17-20, 2009.

    36) Michaud V, Frappier M, Turgeon J. Determination from a large cohort of heart failure patients of

    mRNA Levels of cardiac CYP450s involved in the metabolism of drugs.European ISSX Meeting, Lisbon, Portugal, May 17-20, 2009. P76.

    37) Michaud V, Frappier M, Turgeon J. Cardiac CYP450 mRNA levels in ischemic and non-ischemic hearts

    from a large cohort of patients with end-stage heart failure. Canadian Cardiovascular Congress, Edmonton, Canada, October 24-28 2009. P399-074.

    38) Michaud V, Dumas M-C, Frappier M, Turgeon J Relationship between cardiac CYP450 mRNA levels

    and verapamil metabolism in human heart microsomes. Canadian Cardiovascular Congress, Edmonton, Canada, October 24-28 2009. P396-071.

    39) Michaud V, Shader S, Oliveira M, Colby-Germinario S, Lisovsky I, Wainberg M. Les cellules

    épithéliales de l’endocervix agissent à titre de réservoir transitoire dans l’infection des cellules T par le VIH avec un phénotype X4 ou R5. Journée des étudiants Réseau SIDA/MI FRSQ. November 20, 2009.

  • V.Michaud, BPharm., PhD. C.V. Feb 2019

    21

    Published abstracts (continued) 40) Michaud V, Skrobik Y, Tarasevych V, Colucci P, Turgeon J. Population pharmacokinetics of fentanyl

    during continuous infusion in patients admitted to the intensive care unit. American Society for Clinical Pharmacology and Therapeutics Meeting, Atlanta, March, 2010.

    41) Michaud V, Shader S, Lisovsky I, Oliveira M, Wainberg M. Epithelial vaginal cells from endocervix

    serve as a transitory reservoir for T cell infection by HIV-1 with the X4 phenotype. American Society for Clinical Pharmacology and Therapeutics Meeting, Atlanta, March, 2010.

    42) Huguet J, Michaud V, Turgeon J. In vitro biotransformation of triazolam in human heart microsomes.

    American Society for Clinical Pharmacology and Therapeutics Meeting, Atlanta, March, 2010. Clin Pharmacol Ther, 87(Suppl. 1) : S46 (PII-20)

    43) Michaud V, Frappier M, Champagne M, Brouillette D, Roy D, Taillon I, O’Hara G, Gossard D, Godman

    K, Philips M, Ajami A, Turgeon J. Contribution of CYP4F2 genotypes to the variability of warfarin dose requirements in Caucasian patients. ISSX meeting, Indianapolis, USA, April 2010.

    44) Michaud V, Oliveira M, Gaudette F, Turgeon J, Wainberg M. Métabolisme de l’efavirenz dans les

    cellules sanguines mononuclées du cordon ombilical (CBMC). Journée VIH-CRCHUM, Montreal. May 18 2010.

    45) Michaud V, Schader S, Oliveira M, Colby-Germinario S, Singhroy D, Wainberg M. Effets du pH sur le

    processus d’infection par le VIH dans les cellules vaginales de l’endocervix. Journée VIH-CRCHUM, Montreal. May 18 2010.

    46) Michaud V, Schader S, Oliveira M, Colby-Germinario S, Sloan R, Wainberg M. Effets de la

    progestérone dans le processus de trans-infection du VIH des cellules vaginales de l’endocervix aux cellules T. Journée VIH-CRCHUM, Montreal. May 18 2010.

    47) Michaud V, Frappier M, Champagne M, Brouillette D, Roy D, Taillon I, O’Hara G, Gossard D, Godman

    K, Philips M, Ajami A, Turgeon J. Assessment of the contribution of CYP4F2 genetic polymorphisms on warfarin dose requirements. CSPT meeting, Toronto, Canada, June 2-4 2010. Can J Clin Pharmacol Vol.17 (1);May 2010: 204 (P6) Oral presentation.

    48) Sirhan-Daneau A, Michaud V, Manzini C, Schwab R, Demers A, Roy I, Lafrenchi P, Chauny JM, St-Onge

    M, Gaudette F, Belanger F, Lavigne G, Turgeon J. Role of CYP2D6 in the pharmacokinetics and pharmacodynamics of oxycodone in healthy volunteers during co-treatment with placebo or quinidine. CSPT meeting, Toronto, Canada, June 2-4 2010. Can J Clin Pharmacol Vol.17(1);May 2010: 211 (P20)

    49) Huguet J, Michaud V, Turgeon J. Biotransformation of triazolam in human liver and heart

    microsomes. CSPT meeting, Toronto, Canada, June 2-4 2010. Can J Clin Pharmacol Vol.17(1);May 2010: 228 (P55)

  • V.Michaud, BPharm., PhD. C.V. Feb 2019

    22

    Published abstracts (continued) 50) Michaud V, Frappier M, Champagne M, Brouillette D, Roy D, Taillon I, O’Hara G, Gossard D, Godman

    K, Philips M, Ajami A, Turgeon J. The influence of pharmacogenetics for warfarin dose requirements. Third International Meeting on Pharmacy and Pharmaceutical Sciences. Istanbul, Turkey, June 9-12 2010; PL-15; Symposium on pharmacogenetics and cardiovascular disease.

    51) Michaud V, Frappier M, Champagne M, Brouillette D, Roy D, Taillon I, O’Hara G, Gossard D, Godman

    K, Philips M, Ajami A, Turgeon J. Effects of CYP4F2 genetic polymorphisms on warfarin dose requirements in Caucasian patients initiating therapy. IUPHAR world congress, Copenhagen, Denmark, July 2010.

    52) Skrobik Y, Michaud V, Turgeon J. Delirium and coma in the ICU are associated with drug metabolism

    and transporter activity. American Thoracic Society 2010. 53) Michaud V, Ogburn E, Thong N, Aregbe AO., Quigg TC., Epstein N, Callaghan JT., Flockhart DA., Desta

    Z. Efavirenz induces CYP2C19-hydroxylation and CYP3A4-sulfoxidation of omeprazole. American Society for Clinical Pharmacology and Therapeutics Meeting, Dallas, March, 2011; PIII-41.

    54) Michaud V, Ogburn E, Kreutz Y, Thong N, Aregbe AO, Quigg TC, Flockhart DA., Desta Z. Influence of

    efavirenz on CYP2C19-dependent hydroxylation of omeprazole related to CYP2C19 genetic polymorphisms. American Society for Clinical Pharmacology and Therapeutics Meeting, Dallas, March, 2011; PI-27.

    55) Michaud V, Ogburn E, Thong N, Aregbe AO. Quigg TC, Flockhart DA, Desta Z. Effects of efavirenz on

    the stereoselective disposition of omeprazole in healthy subjects. American Society for Clinical Pharmacology and Therapeutics Meeting, Dallas, March, 2011; PIII-42.

    56) Michaud V, Frappier M, Champagne M, Brouillette D, Roy D, Taillon I, O’Hara G, Gossard D, Godman

    K, Philips M, Ajami A, Turgeon J. CYP4F2 genetic polymorphisms affect warfarin dose requirements in polymedicated patients initiating warfarin therapy. American Society for Clinical Pharmacology and Therapeutics Meeting, Dallas, March, 2011; PI-28.

    57) Skrobik Y, Michaud V, Leger C, Kubes P, Turgeon J. Delirium and coma in the ICU are associated with

    drug metabolism and transporter activity. American Thoracic Society 2011. 58) Michaud V, Ogburn E, Thong N, Aregbe AO, Quigg TC, Flockhart DA, Desta Z. Stereoselective

    induction of omeprazole metabolism by efavirenz. Canadian Society of Clinical Pharmacology Meeting, Montreal, May 24-27 2011.

    59) Michaud V, Ogburn E, Kreutz Y , Thong N, Aregbe AO, Quigg TC, Flockhart DA, Desta Z. Induction of

    omeprazole metabolism by efavirenz as a function of CYP2C19 genotype. Canadian Society of Clinical Pharmacology Meeting, Montreal, May 24-27 2011.

    60) Huguet J, Chehade E, Michaud V, Gaudette F, Turgeon J. Functional activity of human heart

    microsomes expressing CYP2E1. American Society for Clinical Pharmacology and Therapeutics Meeting, Washington, March 2012; PI-30:pS18.

  • V.Michaud, BPharm., PhD. C.V. Feb 2019

    23

    Published abstracts (continued) 61) Huguet J, Michaud V, Gaudette F, Turgeon J. CYP450 functional activities in human heart

    microsomes. American Society for Clinical Pharmacology and Therapeutics Meeting, Washington, March 2012; PI-31:pS19.

    62) Michaud V, Kreutz Y, Skaar T, Ogburn E, Thong N, Flockhart D, Desta Z. Genotype-based estimation

    of CYP2C19 contribution to the elimination of omeprazole in healthy subjects. American Society for Clinical Pharmacology and Therapeutics Meeting, Washington, March 2012; PII-34:pS64.

    63) Michaud V, Ogburn E, Thong N, Desta Z. Evaluation of the use of single plasma samples for

    determination of omeprazole hydroxylation and sulfoxidation indices to phenotype CYP2C19 and CYP3A under induction drug interactions. American Society for Clinical Pharmacology and Therapeutics Meeting, Washington, March 2012; PII-35:pS64.

    64) Leung YH, Lu J, Belanger F, Turgeon J, Michaud V. Drug-transporter interactions : Inhibition of MCT1

    and MCT4 by statins and other acidic drugs. Canadian Society of Pharmacology and Therapeutics Meeting, Toronto, June 2012; 178: #156.

    65) Huguet J, Gaudette F, Michaud V, Turgeon J. Functional Activity of CYP450 2J2, 3A5 and 2E1 in

    Human Heart Ventricles. Canadian Society of Pharmacology and Therapeutics Meeting, Toronto, June 2012; 124; #57.

    66) Leung Y. Hei, Lu J, Belanger F, Turgeon J, Michaud V. Interactions médicamenteuses : inhibition des

    MCT1 et MCT4 par les statines et autres médicaments acides. Club de Recherches Cliniques du Québec. October 2012; 136 #98.

    67) Huguet J, Gaudette F, Michaud V, Turgeon J. Évaluation de l’activité fonctionnelle des CYP450s dans

    les microsomes de cœurs humains. Club de Recherches Cliniques du Québec. October 2012; 138 #100.

    68) Huguet J, Gaudette F, Michaud V, Turgeon J. Développement d’une approche cocktail pour étudier

    l’activité fonctionnelle des CYP2C8, 1A1 et 2D6 dans le cœur humain. 15eme congrès annuel CRCHUM. Montreal. December 18, 2012.

    69) Huguet J, Gaudette F, Michaud V, Turgeon J. A probe drug cocktail to study CYP2C8, 1A1 and 2D6 in the human heart. American Society for Clinical Pharmacology and Therapeutics Meeting, Indianapolis, March 2013; 93(Suppl 1):30.

    70) Leung YH, Lu J, Belanger F, Turgeon J, Michaud V. Drug-transporter interactions: inhibition of MCT1

    and MCT4 by statins and other acidic drugs. American Society for Clinical Pharmacology and Therapeutics Meeting, Indianapolis, March 2013; 93(Suppl 1):60.

    71) Huguet J., Gaudette F., Michaud V., Turgeon J. Functional activity in human heart expressing CYP1A1,

    Annual meeting American Society for Pharmacology and Experimental Therapeutics, Boston, April 20-24 2013.

  • V.Michaud, BPharm., PhD. C.V. Feb 2019

    24

    Published abstracts (continued) 72) Leung YH, Lu J, Belanger F, Turgeon J, Michaud V. The role of MCT1 and MCT4 in drug-induced muscle

    disorders. Annual meeting American Society for Pharmacology and Experimental Therapeutics, Boston, April 20-24 2013.

    73) Huguet J, Sharma S, Fulton S, Gaudette F, Michaud V. Effets de diètes riches en gras sur l’activité des

    CYP450s hépatiques et extra-hépatiques chez des souris. Club de Recherche Clinique du Quebec, Stoneham, Quebec, Sept 2013.

    74) Huguet J, Godoy R, Sharma S, Bélanger F, Gaudette F, Fulton S, Michaud V. Des organes extra-hépatiques doués d’activité métabolique par les CYP450s. Club de Recherche Clinique du Quebec, Stoneham, Quebec, Sept 2013.

    75) Leung YH, Lu J, Bélanger F, Turgeon J, Michaud V. Rôle des transporteurs MCT1 et MCT4 dans les

    désordres musculaires induits par les statines. Club de Recherche Clinique du Quebec, Stoneham, Quebec, Sept 2013.

    76) Huguet J, Gaudette F, Bélanger F, Michaud V, Turgeon J. Intersubject variability of CYP2J2 activity in

    human heart microsomes. Annual meeting American Society for Pharmacology and Therapeutics, Atlanta, 2014. Clin Pharmacol Ther 2014: 95(1); PI-041: S31.

    77) Leung YH, Papillon M, Turgeon J, Michaud V. Statin-specific transport by MCT1 and MCT4. Annual

    meeting American Society for Pharmacology and Therapeutics, Atlanta, 2014. Clin Pharmacol Ther 2014: 95(1); PI-038: S29.

    78) Lu J, Guilarte Moya LG, Leung YH, Gaudette F, Keiser M, Michaud V, Turgeon J. Inhibition of the

    OATP1A2 transporter by tricyclic compounds. Annual meeting American Society for Pharmacology and Therapeutics, Atlanta, 2014. Clin Pharmacol Ther 2014: 95(1); PII-028: S70.

    79) Huguet J, Sharma S, Bélanger F, Gaudette F, Fulton S, Michaud V. CYP450 mediated metabolism in

    extra-hepatic tissues. Annual meeting American Society for Pharmacology and Therapeutics, Atlanta, 2014. Clin Pharmacol Ther 2014: 95(1); PI-042: S30.

    80) Crevier B, Yee J, Jouni S, Therrien R, Mansour S, Nam Nguyen J, Tremblay C, Turgeon J, Michaud V.

    QTVIE : Comparison of the QTc interval between an outpatient HIV-infected population on antiretroviral therapy and two large HIV-negative cohorts. American Society for Pharmacology and Therapeutics meeting, Atlanta, 2014. Late-breaking abstract LBII-013.

    81) Huguet J, Gaudette F, Bélanger F, Michaud V, Turgeon J. Stereoselective and interindividual

    differences in methadone metabolism in human heart microsomes. Annual meeting American Society for Pharmacology and Therapeutics, Atlanta, 2014. Late-breaking abstract LBII-014.

    82) Gravel S, Huguet J, Rousseau E, Gaudette F, Turgeon J, Michaud V. CYP450 mediated drug metabolism

    in human lung tissue. 19th North American ISSX meeting, San Francisco, October 2014.

  • V.Michaud, BPharm., PhD. C.V. Feb 2019

    25

    Published abstracts (continued)

    83) Lu J, Grangeon A, Gaudette F, Keiser M, Michaud V, Turgeon J. Effects of tricyclic compounds on almotriptan transport through OATP1A2. 19th North American ISSX meeting, San Francisco, October 2014.

    84) Huguet J, Bélanger F, Michaud V, Turgeon J. Impact of CYP2J2*7 on drug metabolism in the human

    heart. 19th North American ISSX meeting, San Francisco, October 2014.

    85) Pelletier R, Gravel S, Huguet J, Turgeon J, Michaud V. Metabolism of olanzapine in human heart microsomes. Annual meeting American Society for Pharmacology and Therapeutics, New Orleans, 2015: PII-018.

    86) Gravel S, Huguet J, Gaudette F, Turgeon J, Michaud V. Iloperidone metabolism in human hearts. Annual meeting American Society for Pharmacology and Therapeutics, New Orleans, 2015: PII-015.

    87) Ghazal N, Yeung Y, Z Ngan, Wang H, El-Sakkary M, Bélanger F, Sheehan N, Lebouché B, Turgeon J, Labbé L, Michaud V. Comparison of drug-transporter mRNA expression levels in PBMC from HIV-infected patients with and without diabetes. Annual meeting American Society for Pharmacology and Therapeutics, New Orleans, 2015: PI-031.

    88) Lu J, Grangeon A, Gaudette F, Keiser M, Michaud V, Turgeon J. Effects of tricyclic compounds on

    naratriptan transport through OATP1A2. Annual meeting American Society for Pharmacology and Therapeutics, New Orleans, 2015, :PI-025

    89) Leung YL, Turgeon J, Michaud V. Statin inhibition of lactic acid transport in human skeletal muscle.

    Annual meeting American Society for Pharmacology and Therapeutics, New Orleans, 2015: PII-012.

    90) Pilote S, Kamaliza J, Turgeon J, Michaud V, Simard C, Drolet B. The effect of intracellular methadone on hERG current is modulated by the coexpression of the CYP450 isozyme 2B6. Annual meeting American Society for Pharmacology and Therapeutics, New Orleans, 2015: PII-014.

    91) Yeung YF, Wang H, Ngan Z, El-Sakkary M, Michaud V, Hétu PO, Lebouché B, Sheehan NL. Evaluating Concentrations of Antiretrovirals: Atazanavir, Darunavir and Tenofovir in Subjects with HIV and Type 2 Diabetes Mellitus - a Pilot Study. 16th International Workshop on the Clinical Pharmacology of HIV and Hepatitis Therapy; May 2015

    92) Maximos S, Leung YT, Gravel S, Bélanger F, Gaudette F, Turgeon J, Michaud V. Hepatic and extra-

    hepatic CYP450s activity modulation in C57BL/6 mice fed a high-fat diet. 20th North American International Society of the Study of Xenobiotics, Orlando FL, 2015: P208.

    93) J Lu, F Gaudette, M Keiser, V Michaud, J Turgeon. Effects of tricyclic compounds on zolmitriptan

    transport through OATP1A2. North American meeting of the International Society for the Study of Xenobiotics, Orlando FL, 2015: P250.

  • V.Michaud, BPharm., PhD. C.V. Feb 2019

    26

    Published abstracts (continued) 94) Grangeon A, Gaudette F, Turgeon J and Michaud V. Highly sensitive LC-MS/MS methods for the in

    vivo assessment of human CYP450 activities using small doses of probe-drugs. North American meeting of the International Society for the Study of Xenobiotics, Orlando FL, 2015: P3.

    95) Gravel S, Huguet J, Gaudette F, Turgeon J, Michaud V. Iloperidone metabolism in human heart

    micosomal and cytosolic fractions. North American meeting of the International Society for the Study of Xenobiotics, Orlando, 2015: PII-136.

    96) Leung YH, Turgeon J, Michaud V. Inhibition of lactic acid efflux by atorvastatin in human skeletal

    muscle cells. North American meeting of the International Society for the Study of Xenobiotics, Orlando, 2015: P259.

    97) Gravel S, Grangeon A, Gaudette F, Chiasson JL, Dallaire S, Langelier H, Turgeon J, Michaud V. Type 2 diabetes modulates CYP450 metabolic activities. 10th MDRC annual meeting. Montreal, Quebec, 2016. Oral poster (ranked in the top 10%).

    98) Gravel S, Grangeon A, Gaudette F, Chiasson JL, Dallaire S, Langelier H, Turgeon J, Michaud V. Type 2

    diabetes modulates CYP450 metabolic activities; an important factor of variability in drug response. American Society for Pharmacology and Therapeutics meeting, San Diego 2016. Late-breaking abstract.

    99) Gravel S, Grangeon A, Gaudette F, Belanger F, Chiasson JL, Dallaire S, Langelier H, Turgeon J, Michaud V. Effect du diabete de type 2 sur le metabolism des medicaments par les Cytochromes P450. Annual scientific meeting of Cardiometabolic Health, Diabetes and Obesity Research Network and COLosSUS Congress. Magog-Oford, Quebec, 2017. #51.

    100) Clermont V, Grangeon A, Gaudette F, Barama A, Michaud V. Characterization of CYP450 drug metabolism enzymes along the entire small intestine in humans. American Society for Pharmacology and Therapeutics meeting, Washington DC, 2017: PII-027.

    101) Grangeon A, Clermont V, Barama A, Gaudette F, Turgeon J, Michaud V. Simultaneous absolute protein quantification method of 14 CYP450s in human intestine by mass-spectrometry-based targeted proteomics. American Society for Pharmacology and Therapeutics meeting, Washington DC, 2017: PII-049.

    102) Leung Y, Turgeon J, Michaud V. Loratadine, a potent inhibitor of lactic acid transporters MCT1 and MCT4 in human skeletal muscle cells. American Society for Pharmacology and Therapeutics meeting, Washington DC, 2017: PI-060.

    103) Gravel S, Chiasson JL, Dallaire S, Langelier H, Grangeon A, Gaudette F, Belanger F, Turgeon J, Michaud V. Influence of type 2 diabetes on cytochromes P450 mediated drug metabolism. American Society for Pharmacology and Therapeutics meeting, Washington DC, 2017: PI-038 (within the top 20%).

  • V.Michaud, BPharm., PhD. C.V. Feb 2019

    27

    Published abstracts (continued) 104) Gravel S, Panzini B, Chiasson JL, Gaudette F, Grangeon A, Turgeon J, Michaud V. Effects of type 2

    diabetes on duodenal CYP450 activities. American Society for Pharmacology and Therapeutics meeting, Orlando FL, March 2018: PT-011 & PWIII-004. (Presidential Trainee Award)

    105) Michaud V, Cicali B, Verzicco J, Knowlton CH, Turgeon J. Yearly medical expenditure in patients treated with CYP2D6-dependent opioids and impact of concomitant treatment with CYP2D6 substrate or inhibitor drugs. American Society for Pharmacology and Therapeutics meeting, Orlando FL, March 2018: PII-095.

    106) Cicali B, Verzicco J, Knowlton CH, Turgeon J, Michaud V. Increased risk medication related problems due to concomitant administration of CYP2D6-dependent opioids and CYP2D6 interacting drugs. American Society for Pharmacology and Therapeutics meeting, Orlando FL, March 2018: PII-032.

    107) Michaud V, Turgeon. Pain management pharmacotherapy in the context of polypharmacy and drug-drug interactions. PCS 4th Global Pain Conference, Florence, Italy, August 2018. Oral presentation (08/18/2018).

    108) Michaud V, Tran M, Pronovost B, Bouchard P, Bilodeau S, Alain K, Vadnais B, Franco M, Turgeon J. Impact of GSTA1 polymorphisms on the oral clearance of busulfan in adult patients undergoing hematopoietic stem cell transplantation. International Congres of Personalized Health Care 2nd edition, Montreal, Canada, September 2018. Oral presentation (09/25/2018).

    Accepted abstracts

    1) Tran M, Pronovost B, Bouchard P, Bilodeau S, Alain K, Vadnais B, Franco M, Turgeon J, Michaud V. Influence of GSTA1 Polymorphisms On The Oral Clearance Of Busulfan Using Limited Sampling Methods In Adult Patients Undergoing Hematopoietic Stem Cell Transplantation. American Society for Pharmacology and Therapeutics meeting, Washington DC, March 2019. Selected for the the Special Poster Session: Pharmacogenomics and for the Presidential Trainee Award.

    2) Gravel S, Gaudette F, Chiasson JL, Turgeon J, Michaud V. Use of 4β-hydroxycholesterol plasma concentration as an endogenous biomarker of CYP3A activity: Clinical validation in patients with type 2 diabetes. American Society for Pharmacology and Therapeutics meeting, Washington DC, March 2019.

  • V.Michaud, BPharm., PhD. C.V. Feb 2019

    28

    Professional Manuscripts

    1) Turgeon J, Michaud V. Le cytochrome P450 et les interactions médicamenteuses. L’Actualité Médicale

    2002; 23 (23):3 -5. 2) Michaud V, Turgeon J. Cytochromes P450 et leur rôle clinique. Le Médecin du Québec 2002; 37(8):73-

    83. 3) Michaud V, Turgeon J. Cytochrome P450, drug interactions and the treatment of dementia. Geriatrics

    and Aging 2003; 6(2):22-7. 4) Turgeon J, Michaud V. Tableaux des principaux substrats d’intérêt pour le traitement de la douleur.

    Février 2003.

    5) Michaud V, Turgeon J. Angiotensin converting enzyme inhibitors (ACEIs) and Angiotensin II AT1 receptor blockers (ARBs), comparative charts. Mars 2003.

    6) Michaud V, Turgeon J. L’importance clinique des interactions médicamenteuses reliées aux

    isoenzymes du cytochrome P450: de la fiction à la réalité. Pharmactuel 2003;36(2):88-96. 7) Michaud V, Hreiche R, Turgeon J. Les CYP450 et la gestion des interactions médicamenteuses dans la

    pratique quotidienne. L’Actualité Pharmaceutique 2006; formation continue:1-8. 8) Michaud V, Hreiche R, Turgeon J. CYP450 et gestion des interactions médicamenteuses dans la

    pratique quotidienne. L’Actualité Médicale 2007;7(5) :49-53. 9) Turgeon J, Michaud V. 1, 2, 3 Prescription; 4, 5, 6 Interactions. Le médecin du Québec. 2008;

    43(12) :39-44. 10) Michaud V, Turgeon J. La médecine personnalisée frappe à votre porte. Le médecin du Québec 2008;

    43(12) :75-9. 11) Michaud V, Turgeon J. Inhibiteurs de la pompe à protons, CYP2C19 et clopidogrel, où en sommes-

    nous? Pharmactuel 2010; 43 (4) : 222-4.

    12) Michaud V, Turgeon J. Les interactions médicamenteuses; fictions ou réalités. Bulletin de la Croix-Bleue du Québec. 2012